Nuvectis Pharma Inc expected to post a loss of 40 cents a share - Earnings Preview

Nuvectis Pharma

03/05/2024 13:48

* Nuvectis Pharma Inc  NVCT.OQ   NVCT.O  is expected to show
no
change in quarterly revenue when it reports  results on May 6
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Nuvectis Pharma Inc is
for a
loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nuvectis
Pharma
Inc is $21.00​, above​ its last closing price of $6.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.36       -0.36      -0.41     Missed  -12.3
 Sep. 30 2023  -0.35       -0.34      -0.37     Missed  -8.1
 Jun. 30 2023  -0.29       -0.29      -0.38     Missed  -30.3​
 Mar. 31 2023  -0.44       -0.44      -0.27     Beat    38.8
 ​​Jan.                    -0.38                        
 1 0001                                                 
 Sep. 30 2022  -0.27       -0.27      -0.42     Missed  -55.6​
 Jun. 30 2022  -0.22       -0.23      -0.28     Missed  -20
 Jan. 1 0001   -0.23       -0.23      -0.32     Missed  -39.1
 This summary was machine generated May 3 at 12:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)